Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury

Molecular Endocrinology

Volumn 29, Issue 8, 2015, Pages 1144-1155

  Ashton, Anthony W ^b,e   Le, T Y L ^a,e   Gomez Sanchez, Celso E ^f   Morel Kopp, Marie Christine ^c,e   McWhinney, Brett ^g   Hudson, Amanda ^d,e   Mihailidou, Anastasia S ^a,e  

^a Cardiology Division   (Australia)

^b Division of Perinatal Research   (Australia)

^c Northern Blood Research Centre and Department of Haematology and Transfusion Medicine   (Australia)

^d Sydney Neuro Oncology Group and Bill Walsh Translational Cancer Research Laboratory   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE 3 CARBOXYMETHOXYLAMINE; ALDOSTERONE DERIVATIVE; AMINE; ESTER; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM REGULATED KINASE 1; SPIRONOLACTONE; SUPEROXIDE; UNCLASSIFIED DRUG; ALDOSTERONE; CALMODULIN BINDING PROTEIN; G PROTEIN COUPLED RECEPTOR; GPR30 PROTEIN, RAT; MEMBRANE PROTEIN; MINERALOCORTICOID ANTAGONIST; NERVE PROTEIN; STRN PROTEIN, RAT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELLULAR DISTRIBUTION; CONJUGATION; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; EXPERIMENTAL RAT; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HORMONE RESPONSIVE ELEMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TRANSCRIPTION INITIATION; ANIMAL; CHEMISTRY; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

RATTUS; UTE;

ALDOSTERONE; AMINES; ANIMALS; CALMODULIN-BINDING PROTEINS; MALE; MEMBRANE PROTEINS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL REPERFUSION INJURY; NERVE TISSUE PROTEINS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, MINERALOCORTICOID; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SPIRONOLACTONE; SUPEROXIDES; TRANSCRIPTIONAL ACTIVATION;

EID: 84938379336     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/ME.2014-1410     Document Type: Article

References (67)

1. Griekspoor A, Zwart W, Neefjes J, Michalides R. Visualizing the action of steroid hormone receptors in living cells. Nucl Recept Signal. 2007;5:e003
2. Perrier R, Richard S, Sainte-Marie Y, et al. A direct relationship between plasma aldosterone and cardiac L-type Ca2 current in mice. J Physiol. 2005;569:153-162.
3. Gomez AM, Rueda A, Sainte-Marie Y, et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation. 2009; 119:2179-2187.
4. Genest J, Lemieux G, Davignon A, Koiw E, Nowaczynski W, Steyermark P. Human arterial hypertension: a state of mild chronic hyperaldosteronism? Science. 1956;123:503-505.
5. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomy-opathy. Circulation. 2004;109:1284-1291.
6. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
7. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
8. Lin YH, Wu XM, Lee HH, et al. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens. 2012;30:1606-1613.
9. Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114: 2604-2610.
10. Beygui F, Montalescot G, Vicaut E, et al. Aldosterone and longterm outcome after myocardial infarction: a substudy of the French nationwide Observatoire sur la Prise en Charge Hospitaliere, l’Evolution a un an et les caRacteristiques de Patients Presentant un infArctus du Myocarde Avec ou sans onde Q (OPERA) study. Am Heart J. 2009;157:680-687.
11. Palmer BR, Pilbrow AP, Frampton CM, et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J. 2008;29:2489-2496.
12. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191-202.
13. Asher C, Wald H, Rossier BC, Garty H. Aldosterone-induced increase in the abundance of Na channel subunits. Am J Physiol. 1996;271:C605-C611.
14. Chen SY, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA. 1999;96:2514-2519.
15. Naray-Fejes-Toth A, Fejes-Toth G. The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel. Kidney Int. 2000;57:1290-1294.
16. Bhargava A, Wang J, Pearce D. Regulation of epithelial ion transport by aldosterone through changes in gene expression. Mol Cell Endocrinol. 2004;217:189-196.
17. Kolla V, Litwack G. Transcriptional regulation of the human Na/K ATPase via the human mineralocorticoid receptor. Mol Cell Biochem. 2000;204:35-40.
18. Gekle M, Freudinger R, Mildenberger S, Schenk K, Marschitz I, Schramek H. Rapid activation of Na /H exchange in MDCK cells by aldosterone involves MAP-kinase ERK1/2. Pflugers Arch. 2001;441:781-786.
19. Grossmann C, Benesic A, Krug AW, et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697-1710.
20. Rossol-Haseroth K, Zhou Q, Braun S, et al. Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldoste-rone. Biochem Biophys Res Commun. 2004;318:281-288.
21. Mihailidou AS, Mardini M, Funder JW. Rapid, nongenomic effects of aldosterone in the heart mediated by protein kinase C. Endocrinology. 2004;145:773-780.
22. Fujita M, Minamino T, Asanuma H, et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension. 2005;46:113-117.
23. Alzamora R, Brown LR, Harvey BJ. Direct binding and activation of protein kinase C isoforms by aldosterone and 17-estradiol. Mol Endocrinol. 2007;21:2637-2650.
24. Wehling M, Bauer MM, Ulsenheimer A, Schneider M, Neylon CB, Christ M. Nongenomic effects of aldosterone on intracellular pH in vascular smooth muscle cells. Biochem Biophys Res Commun. 1996;223:181-186.
25. Hayashi H, Kobara M, Abe M, et al. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res. 2008;31:363-375
26. Wehling M, Spes CH, Win N, et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab. 1998;83:3517-3522.
27. Schmidt BM, Montealegre A, Janson CP, et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab. 1999;84:3528-3533.
28. Schmidt BM, Oehmer S, Delles C, et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension. 2003; 42:156-160.
29. Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JM, Danser AH. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol. 2005;145:664-671.
30. Wehling M, Kasmayr J, Theisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am J Physiol. 1991;260:E719-EE726.
31. Gekle M, Silbernagl S, Wunsch S. Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells. J Physiol. 1998;511(Pt 1):255-263.
32. Le Moellic C, Ouvrard-Pascaud A, Capurro C, et al. Early nongenomic events in aldosterone action in renal collecting duct cells: PKC activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol. 2004;15: 1145-1160.
33. Wildling L, Hinterdorfer P, Kusche-Vihrog K, Treffner Y, Oberleithner H. Aldosterone receptor sites on plasma membrane of human vascular endothelium detected by a mechanical nanosensor. Pflugers Arch. 2009;458:223-230.
34. Grossmann C, Husse B, Mildenberger S, Schreier B, Schuman K, Gekle M. Colocalization of mineralocorticoid and EGF receptor at the plasma membrane. Biochim Biophys Acta. 2010;1803:584-590.
35. Ricchiuti V, Lapointe N, Pojoga L, et al. Dietary sodium intake regulates angiotensin II type 1, mineralocorticoid receptor, and associated signaling proteins in heart. J Endocrinol. 2011;211:47-54.
36. Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011a;57:442-451.
37. Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD. Aldosterone mediates its rapid effects in vascular endothelial cells through Gper/Gpr30 activation. Am J Physiol Cell Physiol. 2013;304: C532-C540.
38. Gros R, Ding Q, Davis M, et al. Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol. Can J Physiol Pharmacol. 2011;89:655-663.
39. Coutinho P, Vega C, Pojoga LH, et al. Aldosterone’s rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone’s effect on estrogen action. Endocrinology. 2014;155:2233-2243.
40. Vasudevan N, Kow L-M, Pfaff DW. Early membrane estrogenic effects required for full expression of slower genomic actions in a nerve cell line. Proc Natl Acad Sci USA. 2001;98:12267-12271.
41. Taylor PJ, van Rosendalc SP, Coombesc JS, Gordon RD, Stowasser M. Simultaneous measurement of aldosterone and cortisol by high-performance liquid chromatography-tandem mass spectrometry: application to dehydration-rehydration studies. J Chromatogr B. 2010;878:1195-1198.
42. Ceglarek U, Kortz L, Leichtle A, Fiedler GM, Kratzsch J, Thiery J. Rapid quantification of steroid patterns in human serum by on-line solid phase extraction combined with liquid chromatography-triple quadrupole linear ion trap mass spectrometry. Clin Chim Acta. 2009;401:114-118.
43. Le TYL, Mardini M, Howell VM, Funder JW, Ashton AW, Mihailidou AS. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension. 2012;59:1164-1169.
44. Ashton AW, Ware GA, Kaul DK, Ware JA. Inhibition of tumor necrosis factor-mediated NFkB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem. 2003;278:11858-11866.
45. Laskowski A, Woodman OL, Cao AH, et al. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic pep-tide in neonatal rat cardiomyocytes. Cardiovasc Res. 2006;72:112-123.
46. Peshavariya HM, Dusting GJ, Selemidis S. Analysis of dihydroethidium fluorescence for the detection of intracellular and extracellular superoxide produced by NADPH oxidase. Free Radic Res. 2007;41:699-712.
47. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-1312.
48. Filardo E, Quinn J, Pang Y, et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology. 20074;148:3236-3245.
49. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630
50. Revankar CM, Mitchell HD, Field AS, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol. 2007;2:536-544
51. Latouche C, Sainte-Marie Y, Steenman M, et al. Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology. 2010;151: 4467-4476.
52. Rude MK, Duhaney TA, Kuster GM, et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005;46:555-561.
53. Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev. 2007;28:726-741
54. Gomez-Sanchez CE, de Rodriguez AF, Romero DG, et al. Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology. 2006;147:1343-1348.
55. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005;70:347-351.
56. O’Dowd BF, Nguyen T, Marchese A, et al. Discovery of three novel G-protein-coupled receptor genes. Genomics. 1998;47:310-313.
57. Deschamps AM, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol. 2009;297:H1806-H1813.
58. Jessup JA, Lindsey SH, Wang H, Chappell MC, Groban L. Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS One. 2010;5:e15433
59. Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol. 2009;297:C1178-C1187.
60. Langer G, Bader B, Meoli L, et al. A critical review of fundamental controversies in the field of GPR30 research. Steroids. 2010;75: 603-610.
61. Maggiolini M, Vivacqua A, Fasanella G, et al. The G proteincou-pled receptor GPR30 mediates c-fos up-regulation by 17-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279: 27008-27016.
62. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hi-rata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology. 2008;149:1009-1014.
63. Tan B, Long X, Nakshatri H, Nephew KP, Bigsby RM. Striatin-3 inhibits estrogen receptor activity by recruiting a protein phosphatase. J Mol Endocrinol. 2008;40:199-210.
64. Weil BR, Manukyan MC, Herrmann JL, et al. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery. 2010;148:436-443.
65. Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, Groban L. Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardio-vasc Res. 2012;94:96-104.
66. Delbeck M, Golz S, Vonk R, et al. Impaired left-ventricular cardiac func-tion in male GPR30-deficient mice. Mol Med Rep. 2011;4:37-40.
67. Martensson UE, Salehi SA, Windahl S, et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology. 2009; 150:687-698